PMID- 10993128
OWN - NLM
STAT- MEDLINE
DCOM- 20010118
LR  - 20191025
IS  - 0268-1315 (Print)
IS  - 0268-1315 (Linking)
VI  - 15
IP  - 5
DP  - 2000 Sep
TI  - A double-blind study of the efficacy and safety of sertraline and clomipramine in 
      outpatients with severe major depression.
PG  - 263-71
AB  - This study compared the efficacy and safety of the selective serotonin reuptake 
      inhibitor sertraline with that of the tricyclic antidepressant clomipramine in 
      patients with severe depression, as defined by a baseline 17-item Hamilton 
      Depression Rating Scale (HAM-D) of at least 25. The study included 166 
      outpatients, randomized to double-blind treatment with sertraline (50-200 mg) or 
      clomipramine (50-150 mg) for 8 weeks. The efficacy of both treatments was 
      similar, 74% of patients in the sertraline group and 71% of clomipramine patients 
      being classified as responders at the end-point, as defined by a Clinical Global 
      Impression-Improvement (CGI-I) score of 1 or 2. Mean HAM-D scores fell from 29.8 
      at baseline to 12.3 at endpoint in the sertraline group, and from 29.6-12.7 in 
      the clomipramine group. There were more withdrawals due to adverse events in the 
      clomipramine group than in the sertraline group (17% versus 12%). Dry mouth, 
      tremor, dizziness and constipation were all substantially more common in the 
      clomipramine group, whereas diarrhoea/loose stools was more common in the 
      sertraline group. Overall, sertraline was as effective as clomipramine in this 
      group of severely depressed outpatients, and showed better tolerability.
FAU - Lepine, J P
AU  - Lepine JP
AD  - Hopital Fernand Widal, Paris, France.
FAU - Goger, J
AU  - Goger J
FAU - Blashko, C
AU  - Blashko C
FAU - Probst, C
AU  - Probst C
FAU - Moles, M F
AU  - Moles MF
FAU - Kosolowski, J
AU  - Kosolowski J
FAU - Scharfetter, B
AU  - Scharfetter B
FAU - Lane, R M
AU  - Lane RM
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Int Clin Psychopharmacol
JT  - International clinical psychopharmacology
JID - 8609061
RN  - 0 (Antidepressive Agents)
RN  - 0 (Antidepressive Agents, Tricyclic)
RN  - NUV44L116D (Clomipramine)
RN  - QUC7NX6WMB (Sertraline)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antidepressive Agents/administration & dosage/*therapeutic use
MH  - Antidepressive Agents, Tricyclic/administration & dosage/*therapeutic use
MH  - Clomipramine/administration & dosage/*therapeutic use
MH  - Depressive Disorder/*drug therapy/psychology
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Outpatients
MH  - Sertraline/administration & dosage/*therapeutic use
MH  - Severity of Illness Index
MH  - Sleep/drug effects
MH  - Treatment Outcome
EDAT- 2000/09/19 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/09/19 11:00
PHST- 2000/09/19 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/09/19 11:00 [entrez]
AID - 10.1097/00004850-200015050-00003 [doi]
PST - ppublish
SO  - Int Clin Psychopharmacol. 2000 Sep;15(5):263-71. doi: 
      10.1097/00004850-200015050-00003.